Thierry M. Jahan, MD
Dr. Thierry M. Jahan is a University of California at San Francisco medical oncologist who specializes in the treatment of lung cancer, pleural mesothelioma, and other thoracic malignancies. Over decades of caring for patients, he has a well-deserved reputation for his empathetic and compassionate treatment of his patients and his commitment to finding a cure for lung cancer.[1]
Education and Career
Dr. Jahan received his medical degree from George Washington University and his internship and residency in Internal Medicine at Cedars Sinai Medical Center in Los Angeles. He completed a clinical fellowship in Hematology and Oncology at the University of California San Francisco, after which he joined the faculty.[1]
After joining the staff at UCSF, Dr. Jahan worked with David Jablons, M.D., and co-founded the center’s Thoracic Oncology Program. In 2016, he was inducted into the Council of Master Clinicians, a group of outstanding physicians with exceptional knowledge, superior teaching and communication skills, and the ability to provide compassionate, appropriate, effective, and high-quality patient care.[1]
Professional Memberships and Activities
Dr. Jahan is an active and engaged member of several professional medical associations, including the American College of Physicians, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Association of Northern California Oncologists.[1]
Research
Dr. Jahan has led numerous clinical trials and authored or co-authored numerous peer-reviewed articles, book chapters, and research abstracts. He helped draft the National Comprehensive Cancer Network guidelines for lung cancer treatment and served on the UCSF Committee on Human Research and the Data Safety Monitoring Committee whose guidance helps ensure that clinical trials are conducted safely and ethically. He has been invited to lecture nationally and internationally on lung cancer and mesothelioma.[1]
His most recent publications include:[2]
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomized, open-label, phase 3 trial. Lancet. 2021 01 30; 397(10272):375-386. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. PMID: 33485464.
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432. Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. PMID: 33035459.
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. PMID: 32997124; PMCID: PMC7527870.
